BioNexus Gene Lab (NASDAQ:BGLC) & Vyant Bio (OTCMKTS:VYNT) Critical Review

Vyant Bio (OTCMKTS:VYNT) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Analyst Ratings

This is a breakdown of recent ratings for Vyant Bio and BioNexus Gene Lab, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyant Bio	0	0	0	0	N/A
BioNexus Gene Lab	0	0	0	0	N/A

Valuation & Earnings

This table compares Vyant Bio and BioNexus Gene Lab’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyant Bio	$670,000.00	1.83	-$22.69 million	N/A	N/A
BioNexus Gene Lab	$9.77 million	1.13	-$2.63 million	($0.02)	-31.00

BioNexus Gene Lab has higher revenue and earnings than Vyant Bio.

Profitability

This table compares Vyant Bio and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vyant Bio	-3,474.81%	-151.82%	-97.14%
BioNexus Gene Lab	-26.90%	-32.99%	-26.99%

Insider & Institutional Ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 9.6% of Vyant Bio shares are owned by insiders. Comparatively, 6.8% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

BioNexus Gene Lab beats Vyant Bio on 6 of the 8 factors compared between the two stocks.

About Vyant Bio

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.